On-Treatment ALT Normalization Has No Statistical Significant Impact on Liver Stiffness Regression in Chinese Chronic Hepatitis B Patients with Advanced Fibrosis or Cirrhosis Receiving Tenofovir Disoproxil Fumarate Therapy
单位：[1]Peking University People’s Hospital, Peking University Hepatology Institute, Beijing Key Laboratory for Hepatitis C and Immunotherapy for Liver Disease[2]Henan Provincial People’s Hospital[3]Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China[4]Center of Diagnosis and Treatment for Infectious Diseases of Chinese PLA, Tangdu Hospital, the Fourth Military Medical University[5]Department of Hepatology, The First Hospital of Jilin University[6]Department of Liver Disease, The Affiliated Hospital of Hangzhou Normal University, Hangzhou[7]International Medical Department, Beijing Youan Hospital Capital Medical University[8]Department of Liver Intensive Care Unit, Shanghai Public Health Clinical Center[9]Guangzhou Eighth Municipal People’s Hospital[10]Department of Infectious Diseases, First Hospital of Shanxi Medical University[11]Department of Infectious Disease, The First Affiliated Hospital, Xi’an Jiaotong University,Xi’an, China[12]Department of Infectious Diseases, No. 81 Hospital of People’s Liberation Army, Nanjing[13]Department of Infectious Diseases, Southwest Hospital, Third Military Medical University[14]Department of Hepatology, The Second Hospital of Nanjing[15]Division of Liver Disease, Jinan Infectious Disease Hospital, Shandong University[16]Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing Key Laboratory of Translational Medicine in Liver Cirrhosis, National Clinical Research Center of Digestive Diseases, Beijing, China临床科室国家中心肝病分中心首都医科大学附属北京友谊医院[17]West China Hospital of Sichuan University四川大学华西医院[18]Department of Infectious Diseases, Huashan Hospital Affiliated to Fudan University[19]Department of Infectious Disease, Institute of Infection and Immunology, Affiliated Union Hospital of Tongji Medical College, Huazhong University of Science and Technology华中科技大学同济医学院附属协和医院[20]Cui Xiong, Statistics, Glaxosmithkline (China) R&D Company Limited [21]Medical Affairs, Glaxosmithkline (China) Investment Company Limited
第一作者单位：[1]Peking University People’s Hospital, Peking University Hepatology Institute, Beijing Key Laboratory for Hepatitis C and Immunotherapy for Liver Disease
推荐引用方式(GB/T 7714)：
Wei Lai,Shang Jia,Xie Qing,et al.On-Treatment ALT Normalization Has No Statistical Significant Impact on Liver Stiffness Regression in Chinese Chronic Hepatitis B Patients with Advanced Fibrosis or Cirrhosis Receiving Tenofovir Disoproxil Fumarate Therapy[J].HEPATOLOGY.2018,68:229A-230A.
APA：
Wei, Lai,Shang, Jia,Xie, Qing,Jia, Zhansheng,Gao, Pujun...&Zhu, Mingfen.(2018).On-Treatment ALT Normalization Has No Statistical Significant Impact on Liver Stiffness Regression in Chinese Chronic Hepatitis B Patients with Advanced Fibrosis or Cirrhosis Receiving Tenofovir Disoproxil Fumarate Therapy.HEPATOLOGY,68,
MLA：
Wei, Lai,et al."On-Treatment ALT Normalization Has No Statistical Significant Impact on Liver Stiffness Regression in Chinese Chronic Hepatitis B Patients with Advanced Fibrosis or Cirrhosis Receiving Tenofovir Disoproxil Fumarate Therapy".HEPATOLOGY 68.(2018):229A-230A
医学